Anatara Lifesciences Ltd (ASX:ANR) has been granted of patent for its animal heath product, Detach, a non-antibiotic approach to aid in the control of diarrheal disease (known as scour), developed using bromelain, an extract from pineapple stems.
The patent claims cover an oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The patent is fully owned by Anatara and will expire in August 2038.
CEO, Steven Lydeamore, said the company remains encouraged by the progress in animal health areas, particularly the opportunity to extend into feed products targeting the need for products for growth enhancement without antibiotics or zinc oxide.
The granting of the patent secures our intellectual property position and is a significant milestone towards commercialising our Detach animal health product,” Mr Lydeamore said.
“Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition, and having a product that is registered for use in Australia, we are well placed to leverage our patent as we work towards a commercial deal.”
The BONIFF-SMEC piglet challenge study for enterotoxigenic Escherichia Coli, anticipated to be completed in June 2021, has commenced.
The BONIFF-SMEC study is being done in partnership with Ridley Corporation, where Anatara’s formulated feed additive is combined with Ridley’s semi-moist extruded creep feed for piglets. The project seeks to determine the efficacy of this combined formulation on piglet health, welfare, and performance after weaning and is being conducted at Murdoch University.
The University of New England’s Poultry Hub Australia successfully completed the ANR-pf poultry challenge study for subclinical and necrotic enteritis. The commercial significance is being evaluated by animal feed companies and poultry producers.
“Having focused our efforts on research and development over a number of years, we have developed a strong animal health pipeline and I look forward to providing the market with an update on the commercial significance of both the pig and poultry challenge trials in the coming months,” Mr Lydeamore said.
